Acute Leukemias. - Second Edition - Reno NV USA | Springer Nature Switzerland AG | 2021 - 283 Pages Includes References - Hematologic Malignancies .

Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.

ISBN: 978-3-030-53632-9 978-3-030-53633-6 (eBook)

ISSN: 2197-9766 2197-9774 (electronic) = abnormalities achieved acute leukemia acute lympho acute lymphoblastic leukemia acute myeloid leukemia adult patients agents allogeneic allogeneic HSCT alloHSCT AML AML patients AML-MRC antibody antigen associated azacitidine B-ALL BL blasts blinatumomab Blood bone marrow Cancer CEBPA chemotherapy Clin Oncol clinical trials combination complete remission CRLF2 cycles cytarabine cytogenetic dasatinib decitabine DNA donor dose efficacy Engl evaluated flow cytometry FLT3 fusion gene genetic genomic Hematol hematologic hematopoietic high-risk https://doi hyper-CVAD imatinib immunophenotype improved induction inhibitors inotuzumab intensive chemotherapy Kantarjian karyotype kemia kinase leuke leukemic lymphoma malignancies Marrow Transplant MDS minimal residual disease molecular MRD MRD-negativity mutations myelodysplastic syndrome neoplasms newly diagnosed Nilotinib NPM1 older patients outcomes ozogamicin patients with acute pediatric Ph-like Ph-positive phase Philadelphia chromosome ponatinib prognostic protein R/R AML Ravandi F receptor refractory regimens relapsed/refractory response risk rituximab sorafenib stem cell transplantation T-ALL T-cell targeted therapy therapy-related tion TKI toxicity translocations treated treatment tumor venetoclax

Subjects--Personal Names: --Hematology, Medical / Clinical Medicine, Medical / Hematology, Medical / Oncology / General, Oncology, Acute diseases, Acute leukemia -- Treatment -- Diagnosis.